BACKGROUND: End-stage renal disease (ESRD) is an increasing problem in patients infected with the human immunodeficiency virus (HIV). The use of highly active antiretroviral therapy (HAART) has decreased the morbidity associated with HIV and has prompted renewed interest in renal transplantation. METHODS: We performed four cases of deceased donor renal transplantation in HIV+ recipients and three cases where laparoscopic live donor nephrectomy (LLDN) was utilized to obtain the kidney for transplantation into living-related HIV+ recipients. In the four deceased donor cases, conventional tacrolimus-based immunosuppression, without antibody induction was used. In the three living-related cases, the immunosuppressive regimen was based on two principles: recipient pretreatment and minimal posttransplant immunosuppression. Alemtuzumab 30 mg (Campath 1-H) was used for preconditioning followed by low-dose tacrolimus monotherapy. RESULTS: Of the four deceased donor cases, one patient continues to have good graft function, and another is not yet on dialysis but has significant graft dysfunction. Rejection was observed in three patients (75%). Infectious complications occurred in one patient (25%), all non-acquired immunodeficiency syndrome (AIDs) defining. In the three living-related cases, all had good graft function, and none have experienced acute rejection. HIV viral loads remain undetectable. CD4 counts are slowly recovering. No infectious or surgical complications occurred. There were no deaths in either group. CONCLUSIONS: These data suggest that living-related donor renal transplantation with steroid-free tacrolimus monotherapy in a "tolerogenic" regimen can be efficacious. However, long-term follow-up is needed to confirm this observation.
BACKGROUND: End-stage renal disease (ESRD) is an increasing problem in patients infected with the human immunodeficiency virus (HIV). The use of highly active antiretroviral therapy (HAART) has decreased the morbidity associated with HIV and has prompted renewed interest in renal transplantation. METHODS: We performed four cases of deceased donor renal transplantation in HIV+ recipients and three cases where laparoscopic live donor nephrectomy (LLDN) was utilized to obtain the kidney for transplantation into living-related HIV+ recipients. In the four deceased donor cases, conventional tacrolimus-based immunosuppression, without antibody induction was used. In the three living-related cases, the immunosuppressive regimen was based on two principles: recipient pretreatment and minimal posttransplant immunosuppression. Alemtuzumab 30 mg (Campath 1-H) was used for preconditioning followed by low-dose tacrolimus monotherapy. RESULTS: Of the four deceased donor cases, one patient continues to have good graft function, and another is not yet on dialysis but has significant graft dysfunction. Rejection was observed in three patients (75%). Infectious complications occurred in one patient (25%), all non-acquired immunodeficiency syndrome (AIDs) defining. In the three living-related cases, all had good graft function, and none have experienced acute rejection. HIV viral loads remain undetectable. CD4 counts are slowly recovering. No infectious or surgical complications occurred. There were no deaths in either group. CONCLUSIONS: These data suggest that living-related donor renal transplantation with steroid-free tacrolimus monotherapy in a "tolerogenic" regimen can be efficacious. However, long-term follow-up is needed to confirm this observation.
Authors: Thomas E Starzl; Noriko Murase; Kareem Abu-Elmagd; Edward A Gray; Ron Shapiro; Bijan Eghtesad; Robert J Corry; Mark L Jordan; Paulo Fontes; Tim Gayowski; Geoffrey Bond; Velma P Scantlebury; Santosh Potdar; Parmjeet Randhawa; Tong Wu; Adriana Zeevi; Michael A Nalesnik; Jennifer Woodward; Amadeo Marcos; Massimo Trucco; Anthony J Demetris; John J Fung Journal: Lancet Date: 2003-05-03 Impact factor: 79.321
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: Wolfgang Dummer; Andreas G Niethammer; Roberto Baccala; Brian R Lawson; Norbert Wagner; Ralph A Reisfeld; Argyrios N Theofilopoulos Journal: J Clin Invest Date: 2002-07 Impact factor: 14.808
Authors: Peter G Stock; Michelle E Roland; Laurie Carlson; Chris E Freise; John P Roberts; Ryutaro Hirose; Norah A Terrault; Lynda A Frassetto; Joel M Palefsky; Stephen J Tomlanovich; Nancy L Ascher Journal: Transplantation Date: 2003-07-27 Impact factor: 4.939
Authors: Ron Shapiro; Mark L Jordan; Amit Basu; Velma Scantlebury; Santosh Potdar; Henkie P Tan; Edward A Gray; Parmjeet S Randhawa; Noriko Murase; Adriana Zeevi; Anthony J Demetris; Jennifer Woodward; Amadeo Marcos; John J Fung; Thomas E Starzl Journal: Ann Surg Date: 2003-10 Impact factor: 12.969
Authors: H P Tan; D J Kaczorowski; A Basu; M Unruh; J McCauley; C Wu; J Donaldson; I Dvorchik; L Kayler; A Marcos; P Randhawa; C Smetanka; T E Starzl; R Shapiro Journal: Am J Transplant Date: 2006-08-04 Impact factor: 8.086
Authors: Thomas A Rasmussen; James McMahon; J Judy Chang; Jori Symons; Michael Roche; Ashanti Dantanarayana; Afam Okoye; Bonnie Hiener; Sarah Palmer; Wen Shi Lee; Stephen J Kent; Carrie Van Der Weyden; H Miles Prince; Paul U Cameron; Sharon R Lewin Journal: AIDS Date: 2017-08-24 Impact factor: 4.177